-
With New CEO In Place, Focus For Teva Pharma Turns To 'Execution'
Tuesday, September 12, 2017 - 10:11am | 375Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)’s having a big week, and it’s only Tuesday. The drug manufacturer’s stock popped as much as 24 percent Monday after the board appointed Kåre Schultz, current head of H. Lundbeck A/S and former COO of Novo Nordisk A/S (ADR...
-
Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'
Wednesday, September 21, 2016 - 10:30am | 352Read More...Allergan plc Ordinary Shares (NYSE: AGN)'s acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA) has some analysts wondering: if Allergan is willing to pay a massive 500 percent premium for Tobira, then what could possibly come next? Barrons cited Kevin Kedra, an analyst at Gabelli, who...
-
What's Gabelli Saying About Teva Now?
Wednesday, April 22, 2015 - 11:51am | 319Read More...In a report published Wednesday, Gabelli & Company analyst Kevin Kedra commented on Teva Pharmaceutical Industries Ltd (NYSE: TEVA)'s offer to acquire Mylan NV (NASDAQ: MYL) for $82 per share. Teva argued that the acquisition could realize $2 billion of synergies, resulting in $10 billion...
